Pulmonary Hypertension Clinical Trials
As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for pulmonary hypertension. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.
Questions? See the Clinical Trials FAQs.
Condition:
Idiopathic, heritable, connective tissue disease-associated and HIV-associated pulmonary arterial hypertension
Key Inclusion Criteria:
- Confirmed clinical diagnosis of IPAH, HPAH, PAH-CTD, PAH-HIV
- NYHA Functional Class: II or III
- 18-75 years old
Summary:
This study focuses on patients with pulmonary arterial hypertension (PAH) from the following subgroups: idiopathic PAH (IPAH), heritable PAH (HPAH), PAH associated with connective tissue disease (PAH-CTD) and PAH associated with HIV (PAH-HIV). The study is designed to evaluate the investigational use of a biologic product called CAP-1002. CAP-1002 consists largely of heart stem cells ("CDCs") grown from donated tissue from human heart muscle. The purpose of the study is to determine the maximum feasible dose and safety of CAP-1002 administered by central intravenous infusion (IV line) in PAH patients belonging to one of the subgroups listed above who have been started on PAH-specific medications. CAP-1002 will be used in addition to the participant’s regular treatment regimen.
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
Condition:
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
CAPERE Thrombectomy System Post-Market Clinical Follow Up Study
Condition:
Observational Study
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Condition:
Critical Limb Ischemia (CLI)
Evaluating the Safety and Efficacy of the Indigo® Aspiration System in Acute Pulmonary Embolism (EXTRACT-PE)
Condition:
Pulmonary Embolism
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)
Condition:
Pulmonary Hypertension
An International Pulmonary Embolism Registry Using EKOS (KNOCOUT PE)
Condition:
Pulmonary Embolism and Thrombosis
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Condition:
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
OPsumit USers Registry (OPUS)
Condition:
Pulmonary Arterial Hypertension
Condition:
Pulmonary Hypertension
Key Inclusion Criteria:
- Patients newly treated with Opsumit defined as a new user of therapy, initiated less than or equal to 30 days prior to enrollment visit or at enrollment
- Signed informed consent
Summary:
This observational study focuses on patients who are initiating therapy with a drug called Opsumit for the treatment of pulmonary arterial hypertension or another etiology (cause of disease). The purpose of the OPUS registry is to better understand the use of Opsumit in the clinical practice, including further characterization of the safety profile for the drug. Other goals include describing the demographic and clinical characteristics of patients treated with Opsumit. Opsumit is approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension.
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
Condition:
Pulmonary Hypertension, Heart Failure With a Preserved Ejection Fraction
Condition:
Pulmonary Hypertension
Key Inclusion Criteria:
- At least 18 years old
- Females must not be pregnant or lactating; males and females must use contraception
- Confirmed diagnosis of World Health Organization (WHO) Group 3 pulmonary hypertension
Summary:
The purpose of this study is to evaluate the safety of a drug called treprostinil (Tyvaso) and the effectiveness of inhaled treprostinil in patients with pulmonary hypertension (PH) associated with interstitial lung disease (ILD) or combined pulmonary fibrosis and emphysema (CPFE). Researchers will examine the participant's ability to exercise after taking treprostinil.
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
Condition:
Peripheral Arterial Disease
Condition:
Pulmonary Hypertension
Key Inclusion Criteria:
- At least 18 years old
- Surgical implantation of LVAD
- Evidence of pulmonary hypertension on baseline right heart catheterization
Summary:
The purpose of this study is to evaluate the safety and effects of an investigational drug called macitentan in patients with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation. Pulmonary hypertension is a disorder of the blood vessels of the lungs, which can occur or worsen after implantation of an LVAD. Researchers will assess the effects of macitentan on the properties and function of the heart, as well as on blood pressure in the pulmonary arteries.
A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE)
Condition:
Heart Failure With Preserved Ejection Fraction
Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)
Condition:
Pulmonary Hypertension Associated With HFpEF
TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study (K5-C200)
Condition:
Carotid Arteries